Ohio State Navbar

Directory

Craig Hofmeister, MD


Staff photo

320 W 10th Ave
M200G
Columbus, OH 43210

Phone: (614) 293-7807

Email: hofmeister.7@osu.edu

 

Current OSU Appointments

Associate Professor-Clinical, Hematology

Physician, FGP-Hematology

 

Clinical Interest

Multiple Myeloma

Biographical

I started at Ohio State 1-Aug-2006 as one of two physicians to see patients with plasma cell dyscrasias. When the division of hematology created sections, I led the myeloma section from 2012-2015 until the sections were eliminated and returned to a single division.

FOCUS: My emphasis is clinical and translational research in multiple myeloma, an incurable blood cancer with an average survival of 4-10 years. Over the last 10 years, we have grown and are now one of the largest myeloma programs in the nation with approximately 30 new patients each month, >100 autologous transplants each year, and a panel of >700 patients that we see in clinic.

Nationally I am a member of the myeloma committees of the ALLIANCE cooperative group, steering committee of the Multiple Myeloma Research Consortium, and the Bone Marrow Transplant Clinical Trials Network.

CLINICAL RESEARCH DIRECTIONS: I have published results of high impact journals related to my role as a clinical investigator, but my goal is to work to lay the ground work and achieve vertical steps in the field. I am focused on 1) experimental therapeutics with first-in-man studies or agents with mechanisms never before tested within hematologic malignancies; 2) novel methods to study epidemiological questions and solve clinical trial accrual difficulties by creating a statewide myeloma registry.

DEVELOPMENT OUTREACH TO SUPPORT RESEARCH: Multiple Myeloma Opportunities for Research & Education (MMORE) (www.mmore.org) was a 501(c)(3) 2008-2016 that raised a few million dollars to support myeloma research. MMORE generously supported research at Ohio State University and annually held two large fundraising events – a 5k run in June (moveMMORE) and a gala in February (celebrateMMORE). I was MMORE's primary contact with Ohio State. We will need to continue high impact novel research and focus on philanthropic investment in hopes of attracting other large donors to further support the myeloma program.

Clinical Interest

Bone marrow transplantation

Research Interest

Multiple myeloma

Research Funding

I have recently worked in collaboration with other scientists at Ohio State, primarily Dr. Mitch Phelps (pharmacy) and Dr. Flavia Pichiorri (formerly division of hematology) to create and have two R01's funded by the NCI as part of the multi-PI mechanism. To my knowledge, there is no other myeloma clinical investigator in the U.S. as a PI on an R01.

I am also a co-investigator on grants submitted by Jianhua Yu regarding chimeric antigen receptor (CAR) preclinical studies regarding myeloma.

Academic Advising

2015 Sonya John, The Ohio State University. Graduated 0. Prevalence of Low Testosterone in Multiple Myeloma Patients
2016 Jacqueline Chu, Ohio State University College of Medicine. Graduated 0. VZV reactivation in multiple myeloma
2016 Basir Syed, Ohio State University College of Medicine. Graduated 0. Viral infections in myeloma as a case-control analysis
2014 - 2016 Douglas W, The Ohio State University. Graduated 2016.
2015 - 2016 Yu Kyoung, The Ohio State University. Graduated 0.
 

Licenses

present State of Ohio Medical License: State Medical Board of Ohio
2002 - present Internal Medicine: American Board of Internal Medicine
2005 - present Hematology: American Board of Internal Medicine
2006 - present Oncology: American Board of Internal Medicine
2006 - present Ohio State Medical License: State Medical Board of Ohio
 

Chapters in Books

.

 

Clinical Services

07/01/2006 Outpatient myeloma clinic (James Cancer Hospital, 5th floor)
07/01/2006 Hematology 1 (End-stage lymphoma & myeloma) (James Cancer Hospital)
07/01/2006 Bone marrow transplantation (James Cancer Hospital)
09/01/2009 Hematology 3 & 4 (James Cancer Hospital)

Conferences

Symphony: View-driven software architecture reconstruction

Separation of navigation routing code in J2EE web applications

 

Degrees

1995 B.S., Brown University

1999 M.D., The Ohio State University

2012 M.Public Hlth., The Ohio State University

 

Editorial Activities

2010 - present Drug Therapy
2010 - present Clinical Lymphoma & Myeloma
2010 - present Clinical Cancer Research
2010 - present Clinical Cancer Pharmacology
2010 - present Journal of Clinical Oncology
2010 - present Blood
2012 - present Cancer Chemotherapy and Pharmacology
2013 - present British Journal of Haematology
2014 - present Expert Opinion on Drug Safety
 

Honors

1996 - present Samuel J. Roessler Research Scholarship.
2002 - present Internal Medicine Senior Resident of the Year Award.
2004 - present Clinical Research Training Institute (CRTI). American Society of Hematology.
2009 Imagine MMORE Award. Multiple Myeloma Opportunities for Research and Education.
2011 Business First's Forty Under 40 Award.
2011 Early Career Achievement Award.
2013 - present Certificate of Excellence, Outstanding Achievement in Patient Service. The Ohio State University Wexner Medical Center.
2014 - present Certificate of Excellence, Outstanding Achievement in Patient Service. The Ohio State University Wexner Medical Center.
2015 - present Certificate of Excellence, Outstanding Achievement in Patient Service. The Ohio State University Wexner Medical Center.
2016 - present Certificate of Excellence, Outstanding Achievement in Patient Service. The Ohio State University Wexner Medical Center.
 

Journal Articles

null

"Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma.." Cancer. Vol. 92, no. 9. (November 2001.): -.

.

null

"Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma.." British journal of cancer. Vol. 111, no. 2. (July 2014.): -.

 

Reference Works

January 2003 Hofmeister CC, Forsythe S, Czerlanis C, Stiff P."Should bronchoscopies be routinely performed for post-transplant infiltrates?" . : abstract #683
October 2004 Hofmeister CC, Lau-Schwabe A, Petruzzelli G, Emami B, Thomas S, Clark JI."A Phase I trial of adjuvant radiochemotherapy using docetaxel for resectable high risk squamous cell carcinoma (SCC) of the head and neck" . : Abstract #43-Poster presentation at Malignancies of the Chest and Head & Neck
November 2005 Hofmeister CC, Parthasarathy M, Czerlanis C, Stiff PJ."Autopsies post hematopoietic stem cell transpalnt: a reassessment of their role in patient management." . : abstract #1332
February 2006 Hofmeister CC, Quinn A, Marble D, Peterson A, Bonish BK, Kroll T, Curry J, Nickoloff BJ."Epidermal dendritic cell depletion with myeloablative conditioning that does not recover post transplant." . : Supp 1, 52
February 2008 Bechtel TP, Crawford BS, Gordon SM, Penza S, Hofmeister CC, Benson D, Devine S."An Aprepitant Containing Regimen Controls the Delayed Nausea and Vomiting Associated with High-dose Melphalan Followed by Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma" . : 166-abstract #471
January 2008 Jones JA, Hofmeister CC, Benson D, Byrd J."Use of kyphoplasty/vertebroplasty in multiple myelomaa is associated with a decreased length of hospital stay compared to spinal surgery or radiation, but its uses varies by race, payer and age." .
January 2009 Pichiorri F, Sung-Suk S, Taccioli C, Hofmeister CC, Benson D, Kuehl M, Munker R, Huebner K, Aqeilan R, Croce C."Regulation of expression of multiple miRNAs defines the cellular response to non genotoxic p53 activation in multiple myeloma cells" . : abstract #2637
February 2009 Hamadani M, Benson D, Porcu P, Elder P, Andritsos A, Hofmeister CC, Garzon R, Lin T, Marcucci G, Blum W, Devine S."Evaluation of Rabbit Antithymocyte Globulin (rATG) Dose-Intensity in Patients Undergoing Allogeneic Stem Cell Transplantation (ASCT) Following Reduced Intensity Conditioning (RIC) with Fludarabine, Busulfan and rATG (FBA)" . : 5
December 2009 Jakubowiak A, Reece D, Hofmeister CC, Lonial S, Zimmerman T, Compagnaro E, Schlossman R, Laubach J, Raje N, Anderson T, Griffith K, Hill M, Harvey C, Dollard A, Wear S, Barrickman J, Tendler C, Esseltine DL, Kelley S, Kaminski M, Anderson K, Richardson P."Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin and Dexamethasone in newly diagnosed multiple myeloma: Updated results of Phase I/II MMRC trial" .
December 2009 Richardson P, Hofmeister CC, Jakubowiak A, Zimmerman T, Spear M, Palladino M, Longenecker A, Kelly S, Neuteboom S, Cropp G, Lloyd K, Hannah A, Anderson K."Phase I trial of the novel structure Proteasome Inhibitor NPI-0052 in patients with relapsed and relapsed refractory multiple myeloma (MM)" . : abstract #431
January 2009 Richardson P, Hofmeister CC, Zimmerman T, Chanan-Khan A, Spear M, Palladino M, Longenecker A, Cropp G, Lloyd K, Wear S, Hannah A, Anderson K."Phase I Clinical Trial of NPI-0052, a Novel Proteasome Inhibitor in Patients with Multiple Myeloma" . : abstract #8505
December 2009 Benson D, Hofmeister CC, Padmanabhan S, Abonour R, Suvannasankha A, Mita A, Squiban P, Smith MK, Bakan C, Marzetto M, Andre P, Tollier J, Caligiuri M, Farag S."Novel monoclonal antibody enhances natural killer (NK) cell cytotoxicity against multiple myeloma (MM): Interm phase I trials results" . : abstract #2880
December 2009 Pichiorri F, Suh S, De Luca L, Taccioli C, Benson D, Hofmeister CC, Ageilan R, Croce C."p53-Inducible micrornas 192 and 215 regulate p53 expression and IGF 1 Axis multiple myeloma" . : abstract #1973
December 2009 Hofmeister CC, Benson D, Efebera Y, Farag S, Grever MR."Phase I trial of Lenalidomide and CCI-779 in patients with relapsed multiple myeloma" . : abstract #2884
December 2009 Benson D, Bakan C, Zhang S, Alghothani L, Liang J,Hofmeister CC, Srivastava S, Smith MK, Greenfield C, Andre P, Squiban P, Romagne F, Caligiuri M, Farag S."IPH2101, a novel anti-inhibitory KIR monoclonal antibody, and Lenalidomide combined to enhance the natural killer (NK) cell versus multiple myeloma (MM) effect" . : abstract #4641
January 2009 Hofmeister CC, Richardson P, Zimmerman T, Spear MA, Palladino MA, Longenecker AM, Cropp GF, Lloyd GK, Hannah AL, Anderson K."Clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/refactory multiple myeloma (r/r MM)" . : Abstract #8505
February 2009 Benson D, Hofmeister CC, Hamadani M, Panzner K, Smith M, Penza S, Elder P, Krugh D, O'Donnell L, Devine D."Pre-mobilization bone marrow plasmacytosis predicts successful stem cell mobilization in patients with multiple myeloma receiving lenalidomide-based induction regimens" . : 67-68
January 2009 Jakubowiak AJ, Reece DE, Hofmeister CC, Lonial S, Zimmerman TM, Campagnaro EL, Schlossman RL, Laubach J, Raje NS, Anderson T, Griffith K, Hill M, harvey C, Dollard A, Wear S, Bock T, Tendler C, Esseltine DL, Kelley S, Kaminski MS, Anderson KC, Richardson PG."Lenalidomide, Bortezomib, pegylated liposomal doxorubicin hydrochloride, and dexamethasone in newly diagnosed multiple myeloma: Initial results of phase I/II MMRC trial" . : abstract 8517
January 2009 Jakubowiak A, Hofmeister CC, Camagnaro E, Kendall T, Zimmerman T, Schlossman R, Reece D, Lonial S, Hari M, Hector-Word Z, Griffith K, Tendler C, Esseltine D, Bock T, Kaminski M, Dollard A, Kelly S, Adnerson K, Richardson P."Phase I/II trial of Lenalidomide, Bortezomib, Doxil and Dexamethasone in Frontline Multiple Myeloma (MM)" . : abstract #132
May 2009 Benson DM, Romagne P, Squiban N, Wagtmann N, Farag S, Mita A, Hofmeister CC, Smith M, Bakan C, Caligiuri M."Novel monoclonal antibody that enhances natural kill (NK) cell cytotoxicity against multiple myeloma (MM) preclinical data interim phase I clinical trial results" . : abstract #3032
December 2009 McCarthy P, Owzar K, Stadtmauer E, Giralt S, Hurd H, Hassoun H, Hofmeister CC, Richardson P, Weisdorf D, Pasquini M, Hars V, Kelly M, Postiglione J, Sutherland S, Anderson K, Linker C."Phase III intergroup study of Lenalidomide (CC-5013) versus placebo maintenance therapy following single autologous stem cell transplant for multiple myeloma (CALGB 100104): Initial report of patient accrual and adverse events" . : abstract #3416
November 2010 McCarthy P, Owzar K, Anderson K, Hofmeister CC, Hurd D, Hassoun H, Giralt S, Stadtmauer E, Richardson P, Weisdorf D, Vij R, Moreb J, Callander N, Van Besien K, Gentile T, Isola L, Maziarz R, Gabriel D, Bashey A, Landau H, Martin T, Qazilbash M, Levitan D, McClune B, hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Horowitz M, Shea T, Devine S, Linker C."Phase III intergroup study of Lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma: CALGB 100104" . : Abstract #37
November 2010 Habib J, Dunavin N, Phillips G, Elder P, Tranovich M, Benson D, Hofmeister CC, Byrd JC, Devine SM, Efebera YA."Analysis of 179 patients with newly diagnosed Multiple Myeloma (MM) treated with novel agents followed by autologous stem cell transplantation (ASCT): a retrospective study." . : abstract #1343
November 2010 Wear S, Richardson P, Revta C, Vij R, Fiala M, Lonial S, Francis D, Siegel DS, Schramm A, Jakubowiak A, Harvey C, Reece D, Gul E, Jagannath S, La L, Hofmeister CC, Jansak B, Stewart K, Hagerty R, Wolf J, Davis B, Krishnan A, Duarte L, Zimmerman T, Cisneros A, Kumar S, Birgin A, Ott R, Tasca L, Kelley S, Anderson K, Giusti K."The Multiple Myeloma Research Consortium (MMRC) Model: Reduced time to trial activation and improved accrual metrics" . : Abstract #3803
November 2010 Dunavin N, Habib J, Phillips G, Edler P, Tranovich M, Benson DM, Hofmeister CC, Byrd JC, Devine SM, Efebera YA."Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma" . : Abstract #3564
November 2010 Benson DM, Bakan C, Padmanaban S, Abonour R, Suvannasankha A, Jagannath S, Chari A, Clever D, Kalu C, Collins S, Alghothani Y, Hofmeister CC, Efebera Y, Blanchet S, Caligiuri M, Farag S."IPH2101, a novel anti-inhibitory KIR monclonal antibody for multiple myeloma: Interm Phase I trial results and correlative biologic and safety data" . : Abstract #1966
November 2010 Hofmeister CC, Rieser G, Bowers M, Merritt L, Greenfield C, Efebera Y, Benson DM, Devine SM, de Moor J."Tablet-based assessment of fatigue, depression and pain in myeloma patients: Cohort study of inflammatory cytokines and QOL measures in the newly diagnosed, patients on lenalidomide, and survivors" . : Abstract #3807
November 2010 Hofmeister CC, Bowers M, Lee S, Phelps M, Benson DM, Kraut E, Hicks W, Deam D, Johnson AJ, Farag S, Jones JA, Byrd JC."Phase I trial of flavopiridol in relapsed myeloma: brief response in t(4; 14) with significant neutropenia" . : Abstract #1933
November 2010 Jakubowiak A, Reece D, Hofmeister CC, Lonial S, Zimmerman T, Campagnaro E, Schlossman R, Laubach J, Raje N, Anderson T, Griffith K, Hill M, Harvey C, Wear S, Barrickman J, Tendler C, Esseltine D, Kelley S, Kaminiski M, Anderson K, Richardson P."Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in newly diagnosed Multiple Myeloma (MM): Final results of Phase I/II MMRC trial" . : Abstract #1937
January 2010 McCarthy PL, Owzar K, Anderson KC, Hofmeister CC, Hassoun H, Hurd DD, Stadtmauer EA, Giralt S, Hars V, Linker CA."Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104" . : abstract #8017
January 2010 Benson DM, Padmanabahn S, Hofmeister CC, Bakan C, Abonour R, Suvannasankha A, Efebera Y, Squiban P, Caligiuri MA, Farag SS."A Phase I trial of IPH2101, a novel anti-ihibitory KIR monoclonal antibody, in patient with multiple myeloma" . : Abstract #8139
November 2010 Baiocchi R, Flynn J, Jones JA, Blum KA, Hofmeister CC, Poon J, Small K, Statkevich P, Grever MR, Bannerji R, Byrd JC."Early evidence of anti-lymphoma activity of the cyclin dependent kinase inhibitor Dinaciclib (SCH 727965) in heavily pre-treated low grade lymphoma and diffuse large cell lymphoma patients" . : Abstract #3966
November 2010 Furman R, Eradat H, Switzky J, hayman S, Hofmeister CC, Avignon N, Leonard J, Coleman M, Liao Q, Shah D, Brownell-Buttich S, Lisby S, Lin TS."A Phase II trial of Ofatumumab in subjects with Waldenstrom's macroglobulinemia" . : Abstract #1795
December 2010 Jakubowiak A, Reece D, Hofmeister CC, Lonial S, Zimmerman T, Campagnaro E, Schlossman R, Laubach J, Raje N, Anderson T, Griffith K, Hill M, Harvey C, Dollard A, Wear S, Barrickman J, Tendler C, Esseltine DL, Kelley S, Kaminski M, Anderson K, Richardson P."Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Updated Results of Phase I/II MMRC Trial" . : abstract #1937
November 2011 Wear S, Richardson P, Revta C, Vij R, Fiala M, Lonial S, Mitchell A, Siegel D, Aleman A, Jakubowiak A, Durecki D, Reece D, Gul E, Chari A, Jagannath S, La L, Hofmeister C, Bowers M, Stewart K, Hagerty R, Wolf J, Pelle-Day G, Krishnan A, Duarte L, Zimmerman T, Larsen D, Kumar S, Birgin A, Raje N, Roy V, Maharaj M, Fay J, Messing T, Ott R, Tasca L, Anderson K, and Giusti K.."Health Services and Outcomes Research: Getting Patients the Care They Need - Personalization and Quality of Care for Patients with Malignancies" . : 901
November 2011 Richardson P, Siegel D, Vij R, Hofmeister CC, Jagannath S, Chen C, Lonial S, Jakubowiak J, Bahlis N, Baz R, Larkins G, Chen M, Zaki M, and Anderson K."Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results" . : abstract #634
November 2011 Furman R, Eradat H, DiRienzo C, Hayman S, Hofmeister CC, Avignon N, Leonard J, Coleman M, Advani R, Switzky J, Liao Q, Shah D, Lisby S, Lin T."A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia." . : abstract #3701
November 2011 Wear S, Richardson P, Revta C, Vij R, Fiala M, Lonial S, Mitchell A, Siegel D, Aleman A, Jakubowiak A, Durecki D, Reece D, Gul E, Chari A, Jagannath S, La L, Hofmeister CC, Bowers M, Stewart K, Hagerty R, Wolf J, Pelle-Day G, Krishnan A, Duarte L, Zimmerman T, Larsen D, Kumar S, Birgin A, Raje N, Roy V, Maharaj M, Fay J, Messing T, Ott R, Tasca L, Anderson K, and Giusti K.."The Multiple Myeloma Research Consortium (MMRC): Accelerated Start up and Accrual Metrics Speeds Drug Development." . : abstract #1024
November 2011 Richardson P, Spencer A, Cannell P, Harrison S, Catley L, Underhill C, Zimmerman T, Hofmeister CC, Jakubowiak A, Laubach J, Palladino M, Longenecker A, Lay A, Wear S, Lloyd K, Hannah A, Reich S, Spear M, Anderson K."Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM)" . : abstract #302
November 2011 Richardson PG, Spencer A, Cannell P, Harrison SJ, Catley L, Underhill C, Zimmerman TM, Hofmeister CC, Jakubowiak AJ, Laubach JP, Palladino MA, Longenecker AM, Lay A, Wear S, Lloyd GK, Hannah AL, Reich S, Spear MA, Anderson KC."Myeloma - Therapy, excluding Transplantation: New Agents in Myeloma" . : 653
November 2012 Jagannath S, Hofmeister CC, Siegel DD, Vij R, Lonial S, Anderson KC, Chen M, Zaki M, Richardson PG.."Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) on Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis." . : abstract #450
November 2012 Richardson PG, Hofmeister CC, Siegel DS, Lonial S, Zaki M, Hua Y, Shah S, Wang J, Anderson KC.."MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma." . : abstract #1949
November 2012 Hofmeister CC, Bowers MA, Baiocchi RA, Lozanski G, Humphries K, Blum KA, Porcu P, Penza S, Greenfield CN, Sell M, Earl CT, Zitesman J, Quinion C, Lustberg ME, Andritsos LA, Devine SM.."Post Autologous Transplant Vorinostat (SAHA) in Hish Risk Lymphoma: Phase 1 Study of Vorinostat Maintenance." . : abstract #2004
November 2012 Stewart AK, Vij R, Laubach JP, Hofmeister CC, Hagerty R, Dueck AC, Kumar SK.."Phase I Study of Aurora Kinase Inhibitor MLN8237 and Bortezomib in Relapsed or Refractory Multiple Myeloma." . : abstract #1859
November 2012 Jaglowski SM, Vasu S, Geyer S, Bingman A, Elder P, Yu J, Blum W, Klisovic RB, Penza S, Efebera YA, Hofmeister CC, Benson DM, Muthusamy N, Devine SM, Andritsos LA, Lozanski G.."Immune Reconstitution At Days 30 and 100 Following Allogeneic Stem Cell Transplant and Association with Subsequent Development of Chronic Graft-Versus-Host Disease." . : abstract #1949
November 2012 Hofmeister CC, Bowers MA, Efebera YA, Humphries K, Benson DM, Greenfield CN, Sell M, Devine SM."Phase I Trial of Lenalidomide + Vorinostat After Autologous Transplant in Multiple Myeloma." . : abstract #3114
November 2012 Benson DM, Cohen AD, Munshi NC, Jagannath S, Spitzer G, Hofmeister CC, Zerbib R, Andre P, Efebera YA, Oxier S, Caligiuri MA.."A Phase I Trial of the Anti-Inhibitory KIR Antibody, IPH2101, and Lenalidomide in Multiple Myeloma: Interim Results" . : abstract #4058
November 2012 Stiff A, Rocci A, Hofmeister CC, Omede’ P, Geyer S, Bringhen S, Cascione L, Bingman A, Gambella M, Cavallo F, De Luca L, Guan J, Larocca A, Corry J, Gay F, Efebera YA, Croce UG, Palumbo A, Pichiorri F.."miRNA in Serum and Bone Marrow Plasma Cells From Multiple Myeloma Patients." . : abstract #2921
November 2012 Vij R, Hofmeister CC, Richardson PG, Jagannath S, Siegel DS, Baz R, Chen M, Zaki M, Larkins G, Anderson KC.."Pomalidomide (POM) with Low-Does Dexamethasone (LoDEX) in Patients with Relapsed Refractory Multiple Myeloma (RRMM): Outcomes Based on Prior Treatment Exposure." . : abstract #4070
November 2012 Jaglowski SM, Hofmeister CC, Elder P, Penza S, Efebera YA, Benson DM, Devine SM, Andritsos LA."The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and Multiple Myeloma" . : abstract #4286
November 2012 Hofmeister CC, Liu Z, Bowers MA, Porcu P, Flynn JM, Christian B, Baiocchi RA, Benson DM, Andritsos LA, Greenfield CN, Sell M, Geyer S, Byrd JC, Grever MR.."Phase I Study of AR-42 in Relapsed Multiple Myeloma and Lymphoma." . : abstract #2955
November 2012 Vasu S, Jaglowski SM, Geyer S, Bingman A, Elder P, Yu J, Andritsos LA, Blum W, Klisovic RB, Penza S, Efebera YA, Hofmeister CC, Benson DM, Muthusamy N, Devine SM, Lozanski G.."Differential Distribution of Activated Innate and Adaptive Immune Subsets in G-CSF Mobilized Hematopoietic Stem Cell Allografts May Influence Incidence of Acute (aGVHD) and Chronic Graft-Versus-Host Disease (cGVHD)." . : abstract #4192
November 2012 Hamadani M, Craig M, Remick S, Gibson L, Petros W, Abraham J, Cumpston A, Bunner P, Basu S, Tse W, Hennelly C, Vasu S, Klisovic RB, Blum W, Jaglowski SM, Benson DM, Andritsos LA, Penza S, Hofmeister CC, Geyer S, Devine SM, Efebera YA.."Immunomodulation of Both Donors and recipients with Atorvastatin As a Strategy for the Prevention of Acute Graft-Versus-Host disease (aGVHD): Results of Two Parallel Prospective Trials in Recipients of Matched Sibling Allogeneic Hematopoietic Cell Transplantation (alloHCT)." . : abstract #1942
March 2013 Hofmeister CC."Serum miRNAs add to ISS and FISH to predict PFS and OS in phase 3 trial" . : abstract #322
December 2015 Efebera YA, Rosko AE, Hofmeister CC, Benner J, Bakan C, Stamper K, Lamb T, Hollie D, Sell M, Avigan D, Benson DB."First Interim Results of a Phase I/II Study of Lenalidomide in Combination with Anti-PD-1 Monoclonal Antibody MDV9300 (CT-011) in Patients with Relapsed/Refractory Multiple Myeloma" .
December 2015 Radomska H, Canella A, Jessica C, Rocci A, Luciano C, Cordero H, Joseph L, Caserta E, Ramasamy S, Efebera YA, Volinia S, Hofmeister CC, Pichiorri F."Small RNA Deep Sequencing Highlights the Important Contribution of Mirnas in Regulating IRF4/c-Myc Axis in Myeloma Development" .
December 2015 Ciarlariello D, Harshman S, Canella A, Hade E, Rocci A, Palumbo A, Hofmeister CC, Freitas M, Benson DM, Pichiorri F."Proteomic Characterization of Circulating Extracellular Vesicles Identifies Novel Serum Myeloma Associated Markers" .
December 2015 Hofmeister CC, Berdeja JG, Vesole DH, Suvannasankha A, Parrott T, Abonour R.". TG02, an Oral CDK9-Inhibitor, in Combination with Carfilzomib Demonstrated Objective Responses in Carfilzomib Refractory Multiple Myeloma Patients" .
December 2015 Rosko AE, Hofmeister CC, Efebera YA, Benson DM, Sborov DW, Jaglowski S, Devine S, Wildes TM, Gillahan J, Jones D, Huang Y, Burd CE."Geriatric Assessment Metrics Are Associated with Hospital Length of Stay in Pre-Bone Marrow Transplant Myeloma Patients" .
December 2015 Richardson PG, Hofmeister CC, Raje NS, Siegel D, Lonial S, Laubach JP, Efebera YA, Vesole DH, Nooka AK, Rosenblatt J, Zaki MH, Herring J, Li Y, Shah S, Chen MS, Anderson KC."A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005)" .
December 2015 Sborov DW, Pichiorri F, Nuovo GJ, Benson DM, Efebera YA, Rosko AE, Hofmeister CC."Reolysin Combined with Carfilzomib for Treatment of Relapsed Multiple Myeloma Patients" .
December 2015 Zonder JA, Usmani S, Scott EC, Hofmeister CC, Lendvai N, Berdeja JG, Anderson LD, Hari P, Singhal S, Orloff G, Craig M, Valent J, Lee W, Hart L, Hrom J, Tarantolo S, Faber E, Schiller GJ, Schreiber J, Oliver C, Rush SA, Tunquist B, Ptaszynski M, Raje NS."Phase 2 Study of Carfilzomib (CFZ) with or without Filanesib (FIL) in Patients with Advanced Multiple Myeloma (MM)" .
December 2015 Snoad B, Hudzik S, Sborov DW, Williams N, Jones D, Hofmeister CC."The Majority of Myeloma Patients Are Hypogonadal but This Is Not Associated with High Risk Cytogenetics" .
December 2015 Issa H, Ruppert AS, Elder P, Hofmeister CC, Benson DM, Penza S, Andritsos LA, Klisovic RB, Vasu S, Blum W, Jaglowski SM, Devine SM, Efebera YA."Comparison of Two Doses of Antithymocyte Globulin (ATG) in Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT)" .
March 2016 Issa H, Ruppert AS, Elder P, Hofmeister CC, Benson DM, Penza S, Andritsos LA, Klisovic R."Antithymocyte Globulin (ATG) 4.5 Vs. 6.0 Mg/Kg in Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT)" .
May 2016 Valencia H, Newton HB, Hade E, Sborov DW, Cavaliere R, Poi M, Phelps M, Wang J, Coss CC, Khountham S, Monk P, Olencki T, Shapiro CL, Piekarz R, Hofmeister CC, Grever MR, Welling DB, Mortazavi A."A phase 1 study of AR-42 in patients with advanced solid tumors, including nervous system tumors" .
May 2016 Siegel DSD, van de Donk N, Sonneveld P, Hofmeister CC, Bahlis NJ, Niesvizky R, Sternas LA, Peluso T, Shah S, Slaughter A, Zaki MH, Wang J, San Miguel J."A phase 1b study of durvalumab (MEDI4736) alone or in combination with pomalidomide (POM) with or without low dose-dexamethasone (LoDEX) in patients (pts) with relapsed and refractory multiple myeloma (RRMM)" .
May 2016 Bhatt G, Hofmeister CC, Efebera YA, Benson DM, Sborov DW, Jaglowski SM, Devine SM, Wildes TM, Jones D, Huang Y, Rosko AE."A feasibility study of electronic geriatric assessment for real-time morbidity evaluation" .
December 2016 Li HH, Williams N, Sharma N, Efebera YA, Rosko AE, Benson DM, Hofmeister CC."2420 Anti-Depressant Use in Patients with Multiple Myeloma Less Common Than Expected" .
December 2016 Ghose J, Terrazas C, Viola D, Caserta E, Krishnan A, Hofmeister CC, Satoskar A, Pichiorri F."4479 Daratumumab Impairs Myeloma Cell Adhesion Mediated Drug Resistance through CD38 Internalization" .
December 2016 Auletta JJ, Ardura MI, Vasu S, Huang Y, Zhao Q, Ruppert AS, Shoben A, Elder P, Bingman A, Kitzler R, Lozanski G, Abu-Arja R, Rangarajan HG, Bajwa R, Horwitz EM, O'Donnell L, Jaglowski S, Klisovic RB, Penza S, Efebera YA, Hofmeister CC, Rosko AE, Benson DM, Andritsos LA, Blum W, Devine SM."3410 Early Infection Attenuates Hematologic Malignant Disease Relapse Following Initial Allogeneic Hematopoietic Cell Transplantation" .
December 2016 Cornell RF, Rossi AC, Baz R, Hofmeister CC, Shustik C, Richter JR, Chen C, Vogl DT, Shacham S, Baloglu E, Senapedis W, Ellis J, Friedlander S, Choe-Juliak C, Cubitt CL, Turner JG, Sullivan D, Kauffman M."4509 A Phase 1/2 Study of the Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, KPT-8602, in Patients with Relapsed Refractory Multiple Myeloma" .
December 2016 Richardson DR, Huang Y, Elder P, Newlin J, Kirkendall C, Devine SM, Andritsos LA, Benson DM, Blum W, Efebera YA, Hofmeister CC, Jaglowski S, Klisovic RB, McGinty HL, Penza S, Vasu S, William BM, Rosko AE."1241 Psychosocial Risk Is Associated with High Readmission Rates and Increased Length of Stay for Patients Following Hematopoietic Stem Cell Transplantation" .
December 2016 Ghose J, Russell L, Caserta E, Santhanam R, Jaime-Ramirez AC, Viola D, Krishnan A, Hofmeister CC, Kaur B, Pichiorri F."4467 Exploring the Possibility of Using Herpes Simplex Virus in Oncolytic Virotherapy of Multiple Myeloma" .
December 2016 Culver S, Williams N, Sharma N, Efebera YA, Rosko AE, Benson DM, Hofmeister CC."4444 Relative Clone Size By FISH of Both Del(13q) and Del(17p) Independently Impact Overall Survival" .
December 2016 Auletta JJ, Ardura MI, Vasu S, Huang Y, Zhao Q, Ruppert AS, Shoben A, Elder P, Bingman A, Kitzler R, Lozanski G, Abu-Arja R, Rangarajan HG, Bajwa R, Horwitz EM, O'Donnell L, Jaglowski S, Klisovic RB, Penza S, Efebera YA, Hofmeister CC, Rosko AE, Benson DM, Andritsos LA, Blum W, Devine SM."3409 Cytomegalovirus Reactivation Does Not Increase Subsequent Risk for Acute Graft-Versus-Host Disease, Malignant Disease Relapse, or Infection Following Allogeneic Hematopoietic Cell Transplantation" .
December 2016 Makowski M, Ahmed E, Schlotter S, Pearson R, Kitzler R, Alvarnas JC, Le Rademacher J, Wang Y, Little RF, Akpek G, Ayala E, Devine SM, Kaplan LD, Noy A, Popat UR, Hsu JW, Morris LE, Thompson J, Horowitz MH, Mendizabal AM, Levine AM, Krishnan A, Hade E, Hofmeister CC, Forman SJ, Navarro WH, Ambinder RF, Lozanski G, Baiocchi."1346 Evaluation of Immune Recovery Following Autologous Hematopoietic Cell Transplantation in HIV-Related Lymphoma: Results of the BMT CTN 0803/AMC 071 Trial" .

Softwares

September 2007 Hofmeister, CC."OSU MedNet 21" The Ohio State University
November 2012 Hofmeister, CC."Ohio Myeloma Initiative" http://ohiomyeloma.org

Inventions and Patents

Chimeric Antigen Receptor (CAR) engineered natural killer cells for cancer immunotherapy

Methods and compositions for treating multiple myeloma, specifically AR-42 plus an IMiD

 

Presentations

An Update on the Management of Multiple Myeloma

An Update on the Management of Multiple Myeloma

Myeloma Management in 2007

Diagnosing and Treating Multiple Myeloma in 2008

Diagnosing and Treating Multiple Myeloma in 2008

Stem Cell Transplantation in Multiple Myeloma

An Update from ASH and the 12th Annual International Myeloma Workshop in Washington

Supportive Care in Multiple Myeloma

Multiple Myeloma Update 2010

Using AR-42 to better understand the mechanism of HDAC inhibition

Myeloma 2010: ASCO Update and Survival Advances

Tailoring Treatment to the Individual Patient: Transplantation - Eligible Patients

Spanning the Continuum of Care: Optimizing Patient Outcomes in Multiple Myeloma.

Multiple Myeloma in 2010

Multiple Myeloma '10: Tailoring Treatment to Optimize Patient Outcomes

Supportive Care

Multiple Myeloma '10: Tailoring Treament to Optimize Patient Outcomes

Multiple Myeloma '10: Tailoring Treatment to Optimize Patient Outcomes

HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to Lenalidomide: molecular bases for novel clinical approaches?

Working Better and Not Harder: Myeloma Treatment Advances in Ohio

Expert Forum on Multiple Myeloma

Becoming Proud of Melphalan Again

Plasma cell dyscrasias

Multiple myeloma.

SUPPORTIVE CARE